EEV

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Retrieved on: 
Thursday, August 10, 2023
Gilead Sciences, Duchenne muscular dystrophy, Therapy, Senior, EEV, Clinical trial, Cancer, Genentech, Entrada, CAR, Patient, Ophthalmology, Hematology, Growth, Neurology, Pharmaceutical industry

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023.

Key Points: 
  • BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023.
  • Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics.
  • “Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • “The broad potential of Entrada’s EEV platform to engage intracellular disease-causing targets provides the opportunity to address diseases where treatment options are unavailable or limited.

EQS-News: ENCAVIS AG

Retrieved on: 
Thursday, July 27, 2023
West Coast of Vancouver Island Aquatic Management Board, Primary energy, EEV, Marketing, Electricity, Heinz Werner (psychologist), PV, Wind, KEW, Investment, ISIN, Renewable energy, CFO, MDAX, Security (finance)

Hamburg/Freiburg, 27 July 2023 – The MDAX-listed wind farm and solar park operator Encavis AG (Prime Standard, ISIN: DE0006095003, ticker symbol: ECV) and the Freiburg-based energy supply company badenova AG & Co. KG plan to jointly promote the expansion of Renewable Energies in Germany.

Key Points: 
  • Hamburg/Freiburg, 27 July 2023 – The MDAX-listed wind farm and solar park operator Encavis AG (Prime Standard, ISIN: DE0006095003, ticker symbol: ECV) and the Freiburg-based energy supply company badenova AG & Co. KG plan to jointly promote the expansion of Renewable Energies in Germany.
  • For this purpose, Encavis Energieversorger I GmbH (EEV) will be founded in Hamburg, in which Encavis AG will hold 51% and Kommunale Energiewende GmbH & Co. KG (KEW) will hold 49%.
  • This is clear evidence of the huge demand for our new solutions to supply the market with Renewable Energy,” welcomes Dr Christoph Husmann, Spokesman of the Management Board and CFO of Encavis AG, the cooperation with badenova.
  • He adds: “We have already had very good experiences and successful projects with Encavis in the past and are looking forward to working with them and other partners on further projects.” The contribution of badenova to the supra-regional expansion of the Encavis cooperation is examined project by project and will thus develop over time.

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Muscular Dystrophy Association, Research and development, EEV, DM1, Vertex, Clinical trial, G&A, Research, Duchenne, Entrada, Patient, Episcopal conference, Administration, Astellas Pharma, R, FDA, MDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, General Administration of Sport of China, Therapy, Muscular dystrophy, Conference, Food, Cryptocurrency, Pharmaceutical industry, IND

BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates.

Key Points: 
  • - $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -
    BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates.
  • Under the terms of the agreement, Entrada received an upfront payment of $224 million, as well as an equity investment of $26 million in February 2023.
  • Entrada selected ENTR-601-45 as the second clinical candidate within its Duchenne franchise in January 2023 and plans to submit an IND application in the fourth quarter of 2024.
  • Collaboration Revenue: Collaboration revenue was $25.3 million for the first quarter of 2023 following the closing of the Vertex Agreement in February 2023.

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Retrieved on: 
Tuesday, April 11, 2023
Microtubule, Infection, University of Rochester Medical Center, Human, Partnership, University, EEV, Marketing, Public, Mpox, COVID-19, African, Animal efficacy rule, CFR, Smallpox, Research, Cmax, Cavg, Associate, Development, Patient, Multiple organ dysfunction syndrome, Dentistry, Immunology, Viral, FDA, Death, BARDA, Virus, Pneumonia, Vaccine, Microbiology, Vaccinia

MIAMI, FL, April 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.

Key Points: 
  • These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
  • The purpose of the study was to evaluate the mechanism of antiviral efficacy of sabizabulin, a novel microtubule disruptor, against the prototypical poxvirus vaccinia in cell culture.
  • To assess the ability of sabizabulin to slow or stop vaccinia virus cell-to-cell spread, BSC40 cells were treated with different concentrations of sabizabulin before inoculation with vaccinia virus at a low multiplicity of infection.
  • In this study, sabizabulin, by disrupting microtubules, was able to prevent the export and release of infectious vaccinia virus.

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Retrieved on: 
Tuesday, April 4, 2023
Inflammation, Medical school, University, Duchenne muscular dystrophy, Therapy, Case Western Reserve University, Astellas Pharma, Senior, EEV, Critical Care Medicine (journal), Hospital, Physician, University Hospitals Cleveland Medical Center, Transplant, Eli Lilly, American College of Physicians, Development, Medical director, Patient, Oklahoma Office of the Chief Medical Examiner, American College of Chest Physicians, Growth, Immunology, American College, Infection, Pfizer, Pharmaceutical industry, Medicine

Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma.

Key Points: 
  • Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma.
  • “Bernie is a dynamic life sciences leader and we look forward to having him join our Board of Directors,” said Dipal Doshi, President and Chief Executive Officer of Entrada.
  • Dr. Zeiher was later named Executive Vice President and Therapeutic Area Head when his responsibilities expanded to include the company's development operations and clinical pharmacology departments.
  • He is also a Fellow in the American College of Physicians and the American College of Chest Physicians.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Science, Research and development, Vertex, Entrada, G&A, Therapy, Administration, Research, General Administration of Sport of China, MDA, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Duchenne muscular dystrophy, Food, EEV, Muscular Dystrophy Association, Conference, FDA, EST, R, Neuromuscular junction, DM1, Pharmaceutical industry, Cryptocurrency, IND, Duchenne

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the fourth quarter and full year ending December 31, 2022 and highlighted recent business updates.

Key Points: 
  • BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the fourth quarter and full year ending December 31, 2022 and highlighted recent business updates.
  • Research & Development (R&D) Expenses: R&D expenses were $15.7 million for the fourth quarter of 2022 and $66.6 million for the full year of 2022, compared to $12.4 million and $35.9 million for the same periods in 2021, respectively.
  • General & Administrative (G&A) Expenses: G&A expenses were $9.9 million for the fourth quarter of 2022 and $30.6 million for the full year of 2022, compared to $6.1 million and $15.2 million for the same periods in 2021, respectively.
  • Net Loss: Net loss was $24.6 million for the fourth quarter of 2022 and $94.6 million for the full year of 2022, compared to net loss of $18.4 million and $51.2 million for the same periods of 2021, respectively.

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Retrieved on: 
Thursday, February 9, 2023
DM1, Vertex, Hart–Scott–Rodino Antitrust Improvements Act, Duchenne muscular dystrophy, Degenerative disease, Entrada, HSR, Patient, Research, Therapy, EEV, Pharmaceutical industry

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and closing of the Company’s previously announced strategic collaboration and license agreement with Vertex.

Key Points: 
  • Under the terms of the agreement announced on December 8, 2022, Entrada will receive an upfront payment of $224 million, as well as an equity investment of $26 million at $16.26 per share.
  • Entrada is eligible to receive up to $485 million for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement.
  • The agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for certain research activities related to ENTR-701, as well as additional DM1-related research activities.
  • Vertex will be responsible for global development, manufacturing and commercialization of ENTR-701 and any additional programs stemming from Entrada’s DM1 research efforts.

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

Retrieved on: 
Monday, January 9, 2023
IND, Muscular Dystrophy Association, Therapy, MDA, RNA transfection, Duchenne muscular dystrophy, EEV, Entrada, Conference, DMD, Exon, Patient, Episcopal conference, Investigational New Drug, PMO, Pharmaceutical industry, Duchenne

The Company plans to submit an Investigational New Drug (IND) application in the second half of 2024.

Key Points: 
  • The Company plans to submit an Investigational New Drug (IND) application in the second half of 2024.
  • “There is a profound unmet need for people living with Duchenne and the more than 1,300 people in the US and Europe who are exon 45 skipping amenable,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Entrada plans to present additional data in support of ENTR-601-45 at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2023.
  • ENTR-601-45 is designed to address the underlying cause of Duchenne muscular dystrophy due to mutated or missing exons in the DMD gene.

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Retrieved on: 
Thursday, December 8, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Therapy, Security (finance), Form 10-K, DM1, DMD, Degenerative disease, Woman, Therapeutic index, Central nervous system, CF, Sickle cell disease, Hart–Scott–Rodino Antitrust Improvements Act, Duchenne, Vertex Pharmaceuticals, Biomarker, Patient, EEV, Research, Biology, Disease, Pain, Medication, COVID-19, Multimedia, Annual report, Duchenne muscular dystrophy, Safety, Tissue, Global Research, Beta thalassemia, Cystic fibrosis, Pharmaceutical industry, Fine chemical, Biotechnology, Vertex

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1).
  • Our collaboration with Vertex represents an important step for Entrada as we work to make intracellular therapeutics a reality through our novel EEV approach, said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • ENTR-701, a proprietary Endosomal Escape Vehicle (EEV)-conjugated phosphorodiamidate morpholino oligomer, is the second novel clinical candidate from Entradas growing pipeline of EEV therapeutics.
  • The Companys lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

Retrieved on: 
Tuesday, November 22, 2022
EEV, Conference, Tissue, Therapy, Degenerative disease, Patient, Duchenne muscular dystrophy, DM1, Evercore, Central nervous system, DMD, Therapeutic index, Entrada, Pharmaceutical industry

A live webcast will be available on the Investor Relations section of the Companys website at www.entradatx.com .

Key Points: 
  • A live webcast will be available on the Investor Relations section of the Companys website at www.entradatx.com .
  • A replay will be available on the Entrada website for 90 days following the event.
  • Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable.
  • For more information about Entrada, please visit our website, www.entradatx.com , and follow us on Twitter and LinkedIn .